How does Rystiggo work?
Rystiggo (faricimab-svkn) is a bispecific antibody that targets two pathways involved in neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). It simultaneously inhibits angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A) [1].
What is the role of Ang-2 and VEGF-A in eye diseases?
VEGF-A is a key driver of abnormal blood vessel growth and leakage in the back of the eye, which characterizes wet AMD and DME [1]. Ang-2 can destabilize blood vessels and, in combination with VEGF-A, further exacerbates vascular leakage and inflammation [1].
How does inhibiting Ang-2 and VEGF-A help?
By blocking both Ang-2 and VEGF-A, Rystiggo aims to reduce vascular leakage, suppress inflammation, and inhibit the formation of new, abnormal blood vessels in the retina. This dual action is thought to provide a more comprehensive approach to managing these conditions compared to therapies that target only VEGF-A [1].
When did Rystiggo receive approval?
Rystiggo was approved by the U.S. Food and Drug Administration (FDA) in January 2023 for the treatment of wet AMD and DME [1].
What are the potential benefits of Rystiggo's dual mechanism?
The dual inhibition may offer sustained control of disease activity and potentially longer intervals between treatments. Clinical trials have demonstrated that Rystiggo can maintain vision gains and reduce macular fluid with less frequent dosing compared to some existing therapies [1].
What are the key clinical trial findings for Rystiggo?
Studies like the Phase 3 AVASCI and AVISTA trials showed that Rystiggo achieved non-inferiority to aflibercept in maintaining visual acuity in patients with wet AMD and DME. Importantly, a significant proportion of patients treated with Rystiggo were able to extend their dosing intervals up to every four months, while maintaining these gains [1].
How does Rystiggo compare to other treatments for wet AMD and DME?
Rystiggo offers a different approach by targeting both Ang-2 and VEGF-A. Many current treatments, such as ranibizumab and aflibercept, primarily target VEGF-A. The dual mechanism of Rystiggo may provide an advantage by addressing multiple pathways contributing to disease progression [1].
Are there any known side effects of Rystiggo?
The most common side effects reported in clinical trials included eye inflammation, eye pain, small blood clots in the eye, and visual disturbances. Serious side effects, though rare, can include endophthalmitis (infection inside the eye) and retinal detachment [1].
What is the patent situation for Rystiggo?
Information regarding the patent exclusivity for Rystiggo can be found through resources like DrugPatentWatch.com [2].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/